135 related articles for article (PubMed ID: 16734210)
21. [Detection of urothelial carcinoma of the urinary bladder by multicolor fluorescence in situ hybridization].
Zhang YG; Bi XG; Han YL; Cai Y; Xu X; Wu YP; Yang YL; Ma JH; Zhao P; Jia XM; Wang MR
Ai Zheng; 2007 Feb; 26(2):189-93. PubMed ID: 17298751
[TBL] [Abstract][Full Text] [Related]
22. Molecular pathogenesis of non muscle-invasive bladder cancer: implications for novel targeted therapies.
Zachos I; Tzortzis V; Konstantinopoulos PA; Karatzas A; Gravas S; Melekos M; Papavassiliou AG
Curr Mol Med; 2011 Nov; 11(8):623-32. PubMed ID: 21902654
[TBL] [Abstract][Full Text] [Related]
23. The geriatrics and genetics behind bladder cancer.
Milowsky MI; Kim WY
Am Soc Clin Oncol Educ Book; 2014; ():e192-5. PubMed ID: 24857102
[TBL] [Abstract][Full Text] [Related]
24. Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE).
Highshaw RA; McConkey DJ; Dinney CP
Curr Opin Urol; 2004 Sep; 14(5):295-300. PubMed ID: 15300150
[TBL] [Abstract][Full Text] [Related]
25. Genomic Analysis and Treatment Response of a Bladder Urothelial Carcinoma With Sarcomatoid Variant Histology.
Narayan VM; Gupta S; Davicioni E; Murugan P; Gibb EA; Konety B
Clin Genitourin Cancer; 2019 Oct; 17(5):e888-e892. PubMed ID: 31239241
[No Abstract] [Full Text] [Related]
26. 9p21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology.
Kawauchi S; Sakai H; Ikemoto K; Eguchi S; Nakao M; Takihara H; Shimabukuro T; Furuya T; Oga A; Matsuyama H; Takahashi M; Sasaki K
Hum Pathol; 2009 Dec; 40(12):1783-9. PubMed ID: 19733894
[TBL] [Abstract][Full Text] [Related]
27. [Prospective study of the results at 2 years of one or two cycles of BCG endovesical instillations in the urothelial tumors of the bladder pT1 G3 after completed transurethral resection].
Rischmann P; Gamé X; Mazerolles C; Bittard H; Bouchot O; Descottes JL; Chopin D
Prog Urol; 2005 Dec; 15(6 Suppl 1):1266-70. PubMed ID: 16734216
[No Abstract] [Full Text] [Related]
28. Unlocking precision oncology with FGFR inhibition in urothelial carcinoma.
Sonpavde GP; Subbiah V
Ann Oncol; 2024 Feb; 35(2):150-153. PubMed ID: 37981237
[No Abstract] [Full Text] [Related]
29. Does Schistosoma-associated bladder cancer differ from urothelial cancer? Proof from the laboratory and clinic.
Zaghloul MS
Cancer Genet Cytogenet; 2008 Jan; 180(2):160-2. PubMed ID: 18206545
[No Abstract] [Full Text] [Related]
30. Potential for molecular targeted therapy of HER-2/neu for invasive bladder cancer: examination of gene amplification by fluorescence in situ hybridization.
Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Hirano M; Hayashida K; Mizumukai E; Nanaura H; Honda N
Oncol Rep; 2007 Nov; 18(5):1183-7. PubMed ID: 17914570
[TBL] [Abstract][Full Text] [Related]
31. Targeting the genetic basis of transitional cell carcinoma.
Gomella LG
J Urol; 2006 Jun; 175(6):1986. PubMed ID: 16697780
[No Abstract] [Full Text] [Related]
32. [Clinical pathological expert consensus on HER-2 testing in urothelial carcinoma in China].
;
Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1001-1006. PubMed ID: 34695889
[TBL] [Abstract][Full Text] [Related]
33. The genetics of bladder cancer: a cytogeneticist's perspective.
Wolff DJ
Cytogenet Genome Res; 2007; 118(2-4):177-81. PubMed ID: 18000368
[TBL] [Abstract][Full Text] [Related]
34. FGFR alterations in urothelial carcinoma: Picking the right target.
Hubert P; Selmani Z; Loriot Y; Thiery-Vuillemin A
Bull Cancer; 2021 Jun; 108(6):566-570. PubMed ID: 34020787
[No Abstract] [Full Text] [Related]
35. Neoadjuvant chemotherapy for bladder transitional cell carcinoma: a new standard of care?
Mazhar D; Ali N; Ngan S
Future Oncol; 2007 Feb; 3(1):5-8. PubMed ID: 17280495
[No Abstract] [Full Text] [Related]
36. Granulomatous epididymo-orchitis, a rare complication of intravesical bacillus Calmette-Guérin therapy for urothelial cancer.
Harving SS; Asmussen L; Roosen JU; Hermann G
Scand J Urol Nephrol; 2009; 43(4):331-3. PubMed ID: 19396724
[TBL] [Abstract][Full Text] [Related]
37. Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder.
Vázquez-Lavista LG; Lima G; Gabilondo F; Llorente L
Urology; 2009 Aug; 74(2):414-8. PubMed ID: 19646633
[TBL] [Abstract][Full Text] [Related]
38. Genomics: a preview of genomic medicine.
Karam JA; Shariat SF; Hsieh JT; Knowles MA
BJU Int; 2008 Nov; 102(9 Pt B):1221-7. PubMed ID: 19035885
[No Abstract] [Full Text] [Related]
39. Evaluation of FGFR Alteration Status in Urothelial Tumors.
Bahlinger V; Eckstein M; Hartmann A; Stöhr R
Methods Mol Biol; 2023; 2684():283-291. PubMed ID: 37410241
[TBL] [Abstract][Full Text] [Related]
40. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
